| A pharmacogenetic versus a clinical algorithm for warfarin dosing SE Kimmel, B French, SE Kasner, JA Johnson, JL Anderson, BF Gage, ... New England Journal of Medicine 369 (24), 2283-2293, 2013 | 861 | 2013 |
| Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind … MC Genovese, R Fleischmann, B Combe, S Hall, A Rubbert-Roth, ... The Lancet 391 (10139), 2513-2524, 2018 | 439 | 2018 |
| Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial E Guttman-Yassky, D Thaçi, AL Pangan, HC Hong, KA Papp, K Reich, ... Journal of Allergy and Clinical Immunology 145 (3), 877-884, 2020 | 332 | 2020 |
| Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease WJ Sandborn, BG Feagan, EV Loftus Jr, L Peyrin-Biroulet, G Van Assche, ... Gastroenterology 158 (8), 2123-2138. e8, 2020 | 234 | 2020 |
| Efficacy and safety of upadacitinib monotherapy in methotrexate‐naive patients with moderately‐to‐severely active rheumatoid arthritis (SELECT‐EARLY): a multicenter, multi … R van Vollenhoven, T Takeuchi, AL Pangan, A Friedman, MEF Mohamed, ... Arthritis & Rheumatology 72 (10), 1607-1620, 2020 | 163 | 2020 |
| Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis MEF Mohamed, HS Camp, P Jiang, RJ Padley, A Asatryan, AA Othman Clinical Pharmacokinetics 55, 1547-1558, 2016 | 148 | 2016 |
| Upadacitinib induction and maintenance therapy for Crohn’s disease EV Loftus Jr, J Panés, AP Lacerda, L Peyrin-Biroulet, G D’Haens, ... New England Journal of Medicine 388 (21), 1966-1980, 2023 | 129 | 2023 |
| Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients MHA Shahin, SI Khalifa, Y Gong, LN Hammad, MTH Sallam, M El Shafey, ... Pharmacogenetics and genomics 21 (3), 130-135, 2011 | 125 | 2011 |
| Effects of herbal supplements on drug glucuronidation. Review of clinical, animal, and in vitro studies MEF Mohamed, RF Frye Planta medica 77 (04), 311-321, 2011 | 118 | 2011 |
| Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials B Klünder, MEF Mohamed, AA Othman Clinical pharmacokinetics 57, 977-988, 2018 | 93 | 2018 |
| Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib MEF Mohamed, S Jungerwirth, A Asatryan, P Jiang, AA Othman British Journal of Clinical Pharmacology 83 (10), 2242-2248, 2017 | 86 | 2017 |
| Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities MEF Mohamed, RF Frye Drug metabolism and disposition 39 (9), 1522-1528, 2011 | 70 | 2011 |
| Pharmacokinetics of upadacitinib with the clinical regimens of the extended‐release formulation utilized in rheumatoid arthritis phase 3 trials MEF Mohamed, J Zeng, PJ Marroum, IH Song, AA Othman Clinical pharmacology in drug development 8 (2), 208-216, 2019 | 65 | 2019 |
| 059 A phase 3, randomised controlled trial comparing upadacitinib monotherapy to MTX monotherapy in MTX-naïve patients with active rheumatoid arthritis R van Vollenhoven, T Takeuchi, AL Pangan, A Friedman, MF Mohamed, ... Rheumatology 58 (Supplement_3), kez106. 058, 2019 | 62 | 2019 |
| Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids MEF Mohamed, RF Frye Drug metabolism and disposition 38 (2), 270-275, 2010 | 57 | 2010 |
| Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity MEF Mohamed, T Tseng, RF Frye Xenobiotica 40 (10), 663-669, 2010 | 55 | 2010 |
| Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses … B Klünder, RK Mittapalli, MEF Mohamed, A Friedel, P Noertersheuser, ... Clinical pharmacokinetics 58, 1045-1058, 2019 | 51 | 2019 |
| Use of early clinical trial data to support thorough QT study waiver for upadacitinib and utility of food effect to demonstrate ECG assay sensitivity MEF Mohamed, J Zeng, P Jiang, B Hosmane, AA Othman Clinical Pharmacology & Therapeutics 103 (5), 836-842, 2018 | 47 | 2018 |
| Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication MEF Mohamed, B Klünder, AA Othman Clinical pharmacokinetics 59, 531-544, 2020 | 44 | 2020 |
| Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure‐response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib MEF Mohamed, D Beck, HS Camp, AA Othman The Journal of Clinical Pharmacology 60 (2), 188-197, 2020 | 41 | 2020 |
